The Development of BTK Inhibitors: A Five-Year Update

Bruton’s tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders. To date, five compounds, able to block BTK in an irreversible manner, have been launched in the market, where...

Full description

Bibliographic Details
Main Authors: Bruno Tasso, Andrea Spallarossa, Eleonora Russo, Chiara Brullo
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/23/7411